Mesoblast Ltd (MESO) stock
MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
$11.91−0.54 (-4.34%)
Close on Nov 17, 2026Market cap $1.54BP/E –Yield –
Mesoblast total assets
Total assets on the balance sheet at the end of each period.
Mesoblast's total assets was $773.08M at Jun 30, 2026. For fiscal 2026 it was $773.08M, down 1.5% from the year before. The highest annual figure on record is $784.68M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $773.08M | -1.5% |
| FY2025 | Jun 30, 2025 | $784.68M | +17.3% |
| FY2024 | Jun 30, 2024 | $669.15M | -0.0% |
| FY2023 | Jun 30, 2023 | $669.42M | +1.1% |
| FY2022 | Jun 30, 2022 | $662.14M | -11.1% |
| FY2021 | Jun 30, 2021 | $744.72M | +1.5% |
| FY2020 | Jun 30, 2020 | $733.60M | +12.5% |
| FY2019 | Jun 30, 2019 | $652.12M | -5.8% |
| FY2018 | Jun 30, 2018 | $692.44M | +5.6% |
| FY2017 | Jun 30, 2017 | $655.69M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $773.08M | +15.5% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $782.31M | +16.7% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $784.68M | +17.2% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $653.32M | +0.4% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $669.15M | +0.2% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $670.29M | -2.1% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $669.42M | +1.1% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $650.44M | -4.6% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $668.06M | -5.2% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $684.50M | -5.2% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $662.14M | -11.1% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $681.69M | -11.0% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $704.44M | +2.5% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $721.82M | +1.3% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $744.72M | +1.5% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $766.13M | +15.1% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $687.31M | -0.4% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $712.57M | +9.0% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $733.60M | +12.5% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $665.79M | -1.5% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $690.24M | +0.3% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $653.79M | -5.6% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $652.12M | -0.5% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $675.71M | – |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $688.33M | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $692.44M | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $655.69M | – |
See a number that looks wrong?